This website is intended for healthcare professionals only and contains promotional content.

Report an adverse event here
Link Logo
United Kingdom - English

United Kingdom - English

United Kingdom | English

These country specific websites are specifically intended for healthcare professionals in listed countries only.

Europe

Deutschland - DeutschDeutschland - Deutsch España - EspañolEspaña - Español Italia - ItalianoItalia - Italiano United Kingdom - EnglishUnited Kingdom - English

NOTICE: Kyowa Kirin International has agreed a joint venture with Grünenthal GmbH for the Established Medicines portfolio. The new company, KKI NewCo (known as Grünenthal Meds), is responsible for the content on this page. For more information please click here.​

Abstral-product-image

Abstral®

fentanyl citrate

Abstral® is indicated for the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. Breakthrough pain is a transient exacerbation of otherwise controlled chronic background pain.*1

Adverse Events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse Events should also be reported to Kyowa Kirin International UK NewCo Ltd, known as Grünenthal Meds on +44 (0)1896 664000, email PVUK@grunenthalmeds.com

1

Download PDF

Abstral® (fentanyl (as citrate)) is indicated for the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. Breakthrough pain is a transient exacerbation of otherwise controlled chronic background pain. Please note not all medicines containing opioids are authorised for all types of pain indication. Refer to the summary of product characteristics before prescribing. For advice on the responsible use of opioids, including those indicated for other types of pain, please click here

Average:

  • References

    1. Abstral® Summary of Product Characteristics.

    KKI/INT/ABS/0009 November 2023